Synthekine and MSD collaborate for STK-012 combination trial to treat NSCLC
Synthekine has entered a clinical trial partnership and supply agreement with Merck (MSD) to investigate STK-012 in combination with Keytruda…
All articles by Salong Debbarma
Salong Debbarma
-
-
Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of…
-
Suvoda unveils split budget feature for clinical trial site management
Suvoda has introduced new split budget functionality to its clinical trial software, Budgeting & Benchmarking, supporting sponsors and contract research…
-
Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene therapy targeting…
-
Jaguar Gene Therapy completes Cohort I patient dosing in JAG201 clinical trial
Clinical-stage biotechnology company Jaguar Gene Therapy has completed dosing in Cohort I of its first-in-human clinical trial investigating JAG201 for…
-
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial
Vico Therapeutics has started patient dosing in an expanded cohort under a twice-yearly regimen for its Phase I/IIa clinical trial…
-
C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral ikaros family zinc…
-
Gossamer Bio reports topline Phase III PROSERA outcomes for PAH
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with pulmonary arterial hypertension…
-
Zelluna secures MHRA approval to begin ZIMA-101 trail
Zelluna has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) approval for its…
-
J&J reports long-term QUASAR data for Tremfya in ulcerative colitis
Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term extension study of Tremfya (guselkumab) for ulcerative colitis…